Article
Genetic alterations in the BCR-ABL1 fusion gene related to imatinib resistance in chronic myeloid leukemia.
Leukemia research - 1 Aug 2023
Martínez-Castillo Macario, Gómez-Romero Laura, Tovar Hugo, Olarte-Carrillo Irma, García-Laguna Anel, Barranco-Lampón Gilberto, De la Cruz-Rosas Adrián, Martínez-Tovar Adolfo, Hernández-Zavala Araceli, Córdova Emilio J
Abstract excerpt
Use of the potent tyrosine kinase inhibitor imatinib as the first-line treatment in chronic myeloid leukemia (CML) has decreased mortality from 20% to 2%. Approximately 30% of CML patients experience imatinib resistance, however, largely because of point mutations in the kinase domain of the BCR-ABL1 fusion gene. The aim of this study was to use next-generation sequencing (NGS) to identify mutations related to...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.